Company profile: MBX Biosciences
1.1 - Company Overview
Company description
- Provider of preclinical-stage biotech therapies for rare endocrine diseases, developing investigational candidates including MBX 2109 for consistent parathyroid hormone exposure in hypoparathyroidism, MBX 1416 to prevent severe hypoglycemia in post-bariatric hypoglycemia, MBX 4291, a long-acting GLP-1/GIP receptor co-agonist for obesity, and the PEP Platform for precision endocrine peptide therapeutics.
Products and services
- PEP Platform: A proprietary technology platform that develops precision endocrine peptide therapeutics, enabling targeted creation of hormone-focused products for rare endocrine diseases
- MBX 2109: An investigational drug engineered to deliver consistent parathyroid hormone exposure for treating hypoparathyroidism, maintaining controlled hormone levels to address this rare endocrine disorder
- MBX 1416: An investigational therapy architected to prevent severe hypoglycemia in individuals with post-bariatric hypoglycemia, aiming to reduce dangerous glycemic episodes in this defined patient group
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to MBX Biosciences
Satellos Bioscience
HQ: Canada
Website
- Description: Provider of regenerative medicine therapeutics to stimulate or restore muscle regeneration, leveraging the MyoReGenX proprietary discovery platform to identify muscle diseases and generate novel drug candidates; developing small molecule therapeutics for Duchenne muscular dystrophy via a dystrophin-independent pathway and advancing a series of AAK1 inhibitors to clinical trials to restore muscle repair and regeneration.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Satellos Bioscience company profile →
Edgewise Therapeutics
HQ: United States
Website
- Description: Provider of clinical-stage biopharmaceutical development of small-molecule therapies, including EDG-5506 to protect muscle fibers in rare skeletal muscle disorders (Duchenne and Becker muscular dystrophies), and EDG-7500, an oral, selective cardiac sarcomere modulator for hypertrophic cardiomyopathy and other diseases of cardiac diastolic dysfunction.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Edgewise Therapeutics company profile →
Vidara Therapeutics
HQ: United States
Website
- Description: Provider of specialty pharmaceutical offerings, creating value through accretive product acquisitions or license agreements, sound marketing and distribution, and life cycle management; incorporated in 2003 and based in Dublin, Ireland.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Vidara Therapeutics company profile →
Orphan Technologies
HQ: Switzerland
Website
- Description: Provider of research and development of OT-58, a lead enzyme replacement therapy candidate optimized for classical homocystinuria, a genetic disease characterized by debilitating cardiovascular, skeletal, neurologic, and ophthalmologic complications.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Orphan Technologies company profile →
Lumos Pharma
HQ: United States
Website
- Description: Provider of biopharmaceutical programs developing a novel treatment for Creatine Transporter Deficiency and LUM-201 for Pediatric Growth Hormone Deficiency, an oral small molecule that stimulates growth hormone secretion from the pituitary; supporting the OraGrowtH210 Phase 2 and OraGrowtH212 PK/PD studies, a Predictive Enrichment Markers strategy to identify responders, and an Expanded Access/Compassionate Use program.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Lumos Pharma company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for MBX Biosciences
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to MBX Biosciences
2.2 - Growth funds investing in similar companies to MBX Biosciences
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for MBX Biosciences
4.2 - Public trading comparable groups for MBX Biosciences
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →